Ventrus Biosciences Inc. (VTUS)
-NasdaqCM 2.66 
0.02(0.76%) May 17, 4:00PM EDT
| Prev Close: | 2.64 |
|---|
| Open: | 2.68 |
|---|
| Bid: | 2.04 x 400 |
|---|
| Ask: | N/A |
|---|
| 1y Target Est: | 7.90 |
|---|
| Beta: | 0.61 |
|---|
| Next Earnings Date: | N/A |
|---|
| Day's Range: | 2.64 - 2.69 |
|---|
| 52wk Range: | 1.99 - 12.88 |
|---|
| Volume: | 48,915 |
|---|
| Avg Vol (3m): | 132,316 |
|---|
| Market Cap: | 52.15M |
|---|
| P/E (ttm): | N/A |
|---|
| EPS (ttm): | -1.47 |
|---|
| Div & Yield: | N/A (N/A) |
|---|
The broker you select will become the default broker for Trade Now
Quotes delayed, except where indicated otherwise. Currency in USD.
Headlines
- Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses In Excess Of $100,000 Investing In Ventrus Biosciences, Inc. To Contact The FirmPR Newswire(Sat, May 18)
- Ventrus Biosciences, Inc. Sued by InvestorPR Newswire(Fri, May 17)
- VENTRUS BIOSCIENCES INC FinancialsEDGAR Online Financials(Fri, May 17)
- SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Ventrus Biosciences, Inc. - VTUSPR Newswire(Wed, May 15)
- SHAREHOLDER ALERT: Brower Piven Encourages Investors Who Have Losses in Excess of $300,000 From Investment in Ventrus Biosciences, Inc. to Contact Brower Piven Before the July 8, 2013 Lead Plaintiff Deadline -- VTUSGlobeNewswire(Mon, May 13)
- SHAREHOLDER ALERT: Levi & Korsinsky Notifies Investors With Losses on Their Investment in Ventrus Biosciences, Inc. of Class Action Lawsuit and the Deadline of July 8, 2013 to Seek a Lead Plaintiff Position -- VTUSGlobeNewswire(Mon, May 13)
- Federman & Sherwood Announces That a Securities Class Action Lawsuit Has Been Filed Against Ventrus Bioscences, Inc. (NASDAQ: VTUS)Marketwired(Sun, May 12)
- Bronstein, Gewirtz & Grossman, LLC Announces That A Class Action Has Been Filed Against Ventrus Biosciences, Inc.PR Newswire(Fri, May 10)
- Bernstein Liebhard LLP Announces That A Class Action Has Been Filed Against Ventrus Biosciences, Inc.PR Newswire(Fri, May 10)
- VENTRUS BIOSCIENCES INC Files SEC form 10-Q, Quarterly ReportEDGAR Online(Fri, May 10)
- VENTRUS BIOSCIENCES SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: Kahn Swick & Foti, LLC Reminds Investors With Losses in Excess of $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Ventrus Biosciences, Inc. - VTMarketwired(Thu, May 9)
- Scott+Scott, Attorneys at Law, LLP Files Securities Class Action Lawsuit Against Ventrus Biosciences, Inc. -- VTUSGlobeNewswire(Thu, May 9)
- VENTRUS BIOSCIENCES INC Files SEC form 8-K, Change in Directors or Principal OfficersEDGAR Online(Tue, Apr 9)
- Zeldes & Haeggquist, LLP Announces Investigation of Ventrus Biosciences, Inc.Business Wire(Mon, Apr 8)
- VENTRUS BIOSCIENCES INC Files SEC form 10-K, Annual ReportEDGAR Online(Sun, Mar 17)
Key Statistics
| Forward P/E (1 yr): | N/A |
|---|
| P/S (ttm): | N/A |
|---|
| Ex-Dividend Date: | N/A |
|---|
Analysts
| Annual EPS Est
(Dec-13)
: | -0.87 |
|---|
| Quarterly EPS Est
(Jun-13)
: | -0.21 |
|---|
| Mean Recommendation*: | 1.4 |
|---|
| PEG Ratio (5 yr expected): | -0.18 |
|---|
Business Summary
Ventrus Biosciences, Inc., a development stage specialty pharmaceutical company, focuses on the development and commercialization of late-stage prescription drugs for gastrointestinal disorders.
View More